Plague – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Plague Market Outlook

Thelansis’s “Plague Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Plague treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Plague Overview

Plague, a severe bacterial infection caused by the Gram-negative microorganism Yersinia pestis, exhibits two primary clinical forms: bubonic plague, marked by painful inflammation of lymph nodes referred to as "buboes," accompanied by elevated body temperature and altered health condition, and pulmonary plague, which presents as chest discomfort, a cough producing bloody phlegm, heightened body temperature, changes in clinical state, and disturbances in consciousness. Plague transmission from animals to humans is facilitated by fleas, with rodents acting as the disease reservoir. Additionally, human-to-human transmission occurs through respiratory pathways. Diagnosis hinges on isolating the bacterium from buboes, blood, or respiratory secretions or through serological testing. Multiple classes of antibiotics have proven effective in combating Yersinia pestis, including aminoglycosides, tetracyclines, cotrimoxazole, rifampicin, fluoroquinolones, and others. Left untreated, the disease follows a swiftly fatal course.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: